In studies on aged and brain-lesioned rats the chronic administration of the ACTH(4-9) analog Or92766 has been demonstrated to improve the behavioral performance. For decades ACTH-like peptides have been known to influence behavior (De Wied and Jolles, 1982) . These findings have led in the 1970s to various clinical trials on cognition in young and aged people using these peptides. An extensive review of the results obtained in those studies strongly suggests that ACTH(4-9) predominantly enhances nonselective attention and the ability to sustain attention. ACTH(4-9) disinhibits the processing of stimuli irrespective of their relevance (Born et al., 1986) .
Such an effect of the peptide on attention explains the results reported on sociability, mood, and cognition and the variability of effects on cognition, since these experiments heavily depend on the environmental conditions of the task. The presence of distracting cues may impair the performance, whereas sustained attention may facilitate the performance when only few relevant cues are present. Chronic treatment with the ACTH(4-9) analog of aging rats indicated that hippocampal functioning was improved. reduced the morphological correlates of brain aging in the hippocampus (Landfield, 1987) and counteracted age-related behavioral changes on social behavior and spatial orientation (Spruijt, 1992) . The effects of the peptide on accelerated normal recovery and the necessity of immediate treatment of the lesioned animals have been described as neurotrophic (neuroprotective) in the PNS (Strand et al., 1989; and CNS (Wolterink et al., 1990) . No relation between these neurotrophic effects and the already known "classic" effects on learning and attention has been suggested so far. However, various results in other recovery paradigms, in addition to the neurotrophic (neuroprotective) properties at the time of damage, are reminiscent of the aforementioned effects on attention.
First, deficits in spatial orientation after fimbria fornix (FF) lesion were counteracted by chronic treatment with an ACTH(4-9) analog (Pitsikas et al., , 1991 Spruijt et al., 1990) in a relatively short period as compared to the time (6 months) required for reinnervation (Gage et al., 1983a,b) . The peptide effects on functional recovery in this paradigm cannot be ascribed to accelerated reinnervation of a denervated brain structure. Second, the timing of peptide administration was not essential for restoration of function after paraventricular (Nyakas et al., 1985) and FF lesions (Van Rijzingen, Josephy, Gispen, and Spruijt, unpublished observations). Third, the rate of contralateral compensation was accelerated by ACTH(4-10) following vestibular deafferentation (Gilchrist et al., 1990) .
It is assumed that a peptide-induced state of sustained attention may influence the performance of brain-lesioned animals analogous to what is seen in acutely treated animals. The separately distinguished effects of ACTH-like peptides on neuroprotection (neurotrophic) and sustained attention may have a physiological key element in common: the NMDA receptor. The NMDA receptor is essential for long-term potentiation (Collingridge and Bliss, 1987) a model for changes in the synaptic circuitry underlying memory (McNaughton et al., 1986; Walker and Gold, 199 1) . Selective impairment in place learning can be induced by the NMDA antagonist AP5 (D,L-2-amino-Sphosphonopentanoic acid) as compared to other drugs modulating NMDA receptor activity that has been extensively dem-onstrated (McNaughton et al., 1986; Morris et al., 1986; Leung and Desborough, 1988; Jones et al., 1989; Morris, 1989) and elegantly reviewed by McNamara and Skelton (1993) .
The present study investigates whether treatment with the ACTH(4-9) analog Org2766 interferes at a behavioral level with modulation of NMDA receptor activation. The effects of the peptide on the NMDA antagonist (AP5) and NMDA itself were studied in the Morris water maze and on locomotor activity in a large open field provided with an object, respectively. Since the first goal of the study is to assess a behavioral interaction, the acute behavioral effects of APS and NMDA were used in combination with an acute treatment with the peptide.
Materials
and Methods
Animals
Male Wistar rats, weighing about 250 gm, were housed individually under a reversed day night cycle (lights off at 8 A.M. and lights on at 8 P.M.) in a humidityand temperature (21"(X)-controlled room. Behavioral tests were performed during the dark period. Three hours prior to the onset ofthe experiments animals were brought to the experimental room, which was similar to the rooms used for housing.
Surgery and drugs
Under anesthesia (Hypnorm, 0.1 ml/ 100 gm, s.c.) cannulas were placed intracerebroventricularly as described previously (Brakkee et al., 1979 ) 1 week prior to the onset of the behavioral experiments. AP5 (D,L-2-amino-5-phosphonovaleric acid; Sigma) and the ACTH (4-9) analog Org2766 (Organon B.V., Oss, The Netherlands) were dissolved in 0.9% saline. ACTH(4-9) was used in concentrations of 10 ng (N = 8), 50 ng (N = 8) 100 ng (N = 6) 1 pg (N = S), and 10 pg (N = 8) for subcutaneous injections. The dose of 1 fig given subcutaneously was used for combined treatment with AP5 and NMDA. Preliminary experiments had been carried out to establish an effective dose range for the effects of AP5 in the water maze and demonstrated that animals treated with 10 or 20 fig of AP5 had a very weak muscle tonus and could hardly swim. Therefore, lower doses of AP5 as compared to other studies (Koek et al., 1987; Danysz et al., 1988; Leung et al., 1988; Kim et al., 1991)-3, 4 , and 5 fig--were used in the present study. NMDA (N-methyl-D-aspartate: Siama) was dissolved in a Tris buffer with a nH of 7.2. Preliminarv experiments were conducted to assess the effective dose for the NMDAinduced increase in locomotor activity without the occurrence of convulsions. A dose of 250 ng of NMDA was chosen as the most effective one.
Rats were injected with AP5 (intracerebroventricularly) and ACTH(4-9) (subcutaneously) 15 and 60 min before the test, respectively. Intracerebroventricular injections of ACTH(4-9) or NMDA were given 5 min before the test. Central and peripheral injections were given in a volume of 3 ~1 (intracerebroventricularly) and 0.5 ml (subcutaneously) per rat, respectively. Control rats received the same amount of the dissolvant.
Behavioral tests
The effects of AP5 have been assessed in a Morris water maze and the large open field; the effects of NMDA appeared most sensitive to locomotion in a large open field. Thus, these two tasks were chosen as appropriate tools for revealing interactions of the ACTH(4-9) analog Org2766 with the behavioral consequences of NMDA receptor activation.
Morris water maze. On four consecutive days the animals were given four acquisition trials per day within a period of 15 min in a swimming pool (110 cm diameter, 50 cm high, filled with water made opaque with chalk powder, temperature 26 f 1°C). The basin was divided into four quadrants, each with a starting point, where the rats were put into the water facing the wall. In a random sequence each starting point was used once per day. Rats were given a maximum of 120 set to find the hidden platform (8 cm in diameter, 1 cm below the surface) in a fixed location in the middle of one of the quadrants. They were allowed to stay on it for 30 sec. If they did not find the platform, the experimenter put them onto it for 30 sec. Latencies to find the platform and distance swum were automatically registered with a video computer system developed by Spruijt et al. (1992) . Both latency times and distances swum to reach the platform have been measured; no differences between latencies and distances have been found. Therefore, only the latencies have been given in the Results. Rats were treated every day before they performed the water maze task. Large open field. A circular arena (140 cm diameter; sidewall 50 cm high) made of dark polyester material was used. A metal object of 15 x 15 x 15 cm was placed in the center of the arena. The same computerized system as described above was used to measure the distance walked and the time spent in the periphery of the arena and in the vicinity of the object (40 cm diameter) during a period of 10 min. Pilot studies indicated that possible differences in the pattern of locomotion between different groups are strongly provoked by the presence of an object in the center of the arena.
Experimental design
Prior to the experiments with AP5, which involved large numbers per group, the effect of ACTH(4-9) alone was extensively studied. Previous studies on recovery have shown that the behavior of nonlesioned animals-repeatedly treated with the peptide alone-was not affected in the paradigms used. In order to investigate whether the acute treatment of the peptide in various doses did affect Morris maze behavior, a doseresponse (doses are mentioned above) study preceded the actual experiment. It was necessary to do the control groups in advance since the number of animals that can be run on one day the Morris maze is limited and we did not want to restrict the number of animals in the other groups. In the first experiment rats were injected intracerebroventricularly with 3, 4, and 5 pg AP5 and vehicle (8-10 rats per group) and tested in the water maze. In the second experiment the effect of the ACTH(4-9) analog on the AP5-induced impairment of performance in the water maze was assessed. Rats received 3 pg of AP5 only (N = 8) or combined with subcutaneous pretreatment of ACTH(4-9) (N = 17) or saline (N = 17). A similar experiment was done with 5 pg of AP5 (seven or eight rats per group). In the third experiment the effects of NMDA and the interaction of AP5 and ACTH(4-9) with NMDA were assessed on locomotor activity in a large open field. Five groups of rats (7-10 animals per group) were treated with vehicle, 3 rg of AP5, 250 ng of NMDA, 3 pg of AP5 plus 250 ng of NMDA, and 1 rg of ACTH(4-9) plus 250 ng of NMDA. In all experiments, naive groups of rats were used. AP5, and NMDA were injected according to the time schedule described above.
Results
Acute treatment with the various doses of the ACTH(4-9) analog does not affect the performance in the water maze task (as assessed with an ANOVA on one factor with repeated measurements; Fig. 1 ). Figure 2 depicts the mean latencies required by the animals treated with different doses of AP5 to find the platform. A regression analysis over all days showed a significant effect for the dose (T = 2.5; P < 0.016). This analysis was followed by a regression analysis per day. On day 2 a significant effect of the dose was reached (T = 2.5; P < 0.05). In Figure 3 the effect of the ACTH(4-9) analog on the impairment induced by 3 pg of AP5 is illustrated by the latency times to find the platform over the days for each group. An ANOVA with repeated measurements followed by univariate F tests yielded an overall difference between the groups [F(2,37) = 5.8; P < O.Ol]. A post hoc Tukey HSD test showed that the differences between the groups are due to significant differences on day 2 and day 4 between the groups treated with AP5 alone and AP5 combined with the ACTH(4-9) analog (P < 0.05). Over all days the peptide-treated group did not differ from the control group. The effect of the ACTH(4-9) analog on 5 Fg AP5 is shown in Figure  4 . Again, AP5 impaired the performance, but now the effect of AP5 was not significantly affected by pretreatment with the ACTH(4-9) analog [F(2,13) = 2.8; P < 0.11, although the curve representing the latency times of animals treated with the ACTH(4-9) analog paralleled those of the APS-treated animals at a lower level. (4-9) did not influence the performance in the Morris water maze. This figure presents the mean latency times (and SEM) of several groups of rats-injected with 10 ng, 50 ng, 100 ng, lpg, and 10 wg of the ACTH(4-9) analog and saline 60 min before the four acquisition trials every day.
In Figure 5 the distance run or walked in the exploration arena is given for the various groups at the periphery of the arena and in the center where the object was located. The main differences are to be seen for locomotor activity at the periphery [F(4,41) = 16.8; P < O.OOOl]. A post hoc Tukey test demonstrated that the NMDA-treated animals ran significantly longer distances than all other groups (P < 0.001). Rats treated with NMDA and AP5 or ACTH(4-9) did not differ from each other, but both differed from the control group (P < 0.05). NMDAtreated animals ran more than twice the distance as compared to the controls. Both the antagonist AP5 and the ACTH(4-9) analog counteracted this dramatic increase in running behavior for more than 50%. In the middle of the arena an significant overall effect was seen [F(4,4 1) = 17.0; P < 0.000 11, which was primarily due to the increase for the APS-treated group as shown by a Tukey test, showing that this group walked more in the center than all other groups.
Discussion
The acquisition of spatial orientation is impaired by a relatively low dose of AP5 (3 pg), which is in agreement with findings of others (McNaughton et al., 1986; Morris et al., 1986; Danysz et al., 1988; Kim et al., 199 l) , who suggested that pretreatment with NMDA or antagonists affects the acquisition of a task. Our induced impairment in the Morris maze. Rats were treated as described in Figure 3 with the exception that a higher dose of AP5 (5 rg) was used.
pilot experitqents emphasize the importance of using low doses of AP5, since higher doses resulted in motor disturbances interfering with the swimming ability of the rats. The effect of the lowest dose that affected water maze performance was counteracted by a pretreatment with the ACTH(4-9) analog. Although the higher dose of 5 kg of AP5 seemed affected, this difference was not significant. Apparently, only the low dose of APS can be counteracted by 1 pg of ACTH(4-9). Interestingly, the profound effect of the agonist NMDA on explosive running behavior was also counteracted by the subcutaneously administered peptide. The magnitude of the peptide effect was similar to the effect of the antagonist AP5, despite the differences in the route of administration (subcutaneous vs intracerebroventricular), indicating that the ACTH(4-9) analog very potently antagonizes the running behavior induced by NMDA. The peptide given alone in various doses and via different routes of admin- This lack ofany similarity with the NMDA agonist or antagonist indicates that only changes in NMDA receptor activity are modulated; apparently, peptide efficacy appears only if the experimental conditions result in such changes. The finding that ACTHlike peptides might modulate NMDA receptor activity has two major implications: (1) these effects suggest a linkage between the acute behavioral effects usually associated with attention and the effects seen after chronic treatment that have been observed in lesion and/or aging paradigms; (2) this finding may contribute to the elucidation of the pharmacological mechanisms underlying peptide efficacy, which have not yet been identified, but relations between ACTH-like peptides and opioid systems and between these peptides and excitatory neurotransmission have been suggested in previous studies. Both implications will be discussed separately.
Enhanced recovery by modulation of NA4DA receptor activity It is assumed that chronic treatment has similar but longerlasting effects than acute treatment. For understanding the variety of results in recovery studies it is important to realize that modulatory effects of chronic peptide treatment on NMDA receptor activity may affect functional recovery after brain damage in different ways. First, mechanical and neurotoxic lesions result in depolarization and release/leakage of transmitters such as excitatory amino acids (Choi, 1988) ; counteracting the subsequent NMDA-receptor activation has neuroprotective effects. Beneficial effects ofACTH fragments administered immediately after the damage as seen in various studies (Isaacson and Poplawski, 1983; Hannigan and Isaacson, 1985; Nyakas et al., 1985; Spruijt etal., 1990 : Wolterinket al., 1990 Attellaetal., 1992) may be partly the consequence of such neuroprotective effects of NMDA receptor modulation. Second, modulation of NMDA receptor activation by peptide treatment with a delay to the time of the damage, but shortly before the time of testing, may affect the performance. It is assumed then that facilitation of NMDA receptor activation forms part of the underlying mech- effects on behavior are independent of the damage and reminiscent of the "classical" behavioral effects in cognition paradigms in animals and human studies; also in recovery studies the nature of the change in behavioral performance depends on the experimental conditions of the tasks and are, therefore, not necessarily recognized as an improvement (Nyakas et al., 1985; McDaniel et al., 1989; Spruijt et al., 1990) . The efficacy of enhanced attention as such in FF-lesioned animals on performance is in agreement with results obtained in experiments showing that additional extra environmental cues compensated for the deficit in performance of the lesioned animals (Maho et al., 1991) . Furthermore, results obtained in other studies on recovery (Hannigan and Isaacson, 1985; McDaniel et al., 1989) also suggest an effect of the peptide on attention. Brain damage, especially when it concerns the limbic system, involves disturbances in attention; therefore, peptide efficacy on attention may more easily be detected in lesioned animals as compared to intact animals. Third, a long-lasting enhanced state of attention after chronic peptide treatment (Landfield, 1987; Spruijt, 1992) may indirectly influence synaptic plasticity as is seen in aging studies. The chronic peptide effects (1) on age-related social behavior and spatial orientation (Spruijt, 1992) (2) on a diminished morphological index of brain aging (Landfield, 1987) and (3) on the preserved number of hippocampal mineralocorticoid receptors (Reul et al., 1988) and the inactivation of mineralocorticoid antagonist (RU-283 18) by the peptide (Oitzl et al., 1993) are in agreement with a peptide-induced state of sustained attention. There is a clear relation between the behavioral state of an animal and facilitation of synaptic plasticity. Bramham and Srebo (1989) showed that long-term potentiation and long-term depression are strongly modulated by alertness. They presume that general stimulation of CNS activity promotes functional recovery. Also the peptide-facilitated compensation ofother brain regions after lesions (Igarashi et al., 1988; Gilchrist et al., 1990) may be induced by a modulatory action of the peptide on the behavioral state and subsequently the synaptic plasticity.
The underlying neural substrate There is one study suggesting that the ACTH fragment (4-10) affects directly the NMDA receptor complex (Trifiletti and Pranzatelli, 199 1) . However, we extensively investigated the effects of our fragment (a 4-9 analog) alone and did not find any effect that could be associated either with a noncompetitive antagonist or with a competitive (ant)agonist. Thus, it seems more likely that peptide effects are the result ofan indirect action on NMDA receptor activity. NMDA in low doses induces enhanced locomotor activity; in higher doses (> 300 ng) explosive motor running is observed, which is similar to behaviors preceding convulsions induced by GABAergic antagonists (Spruijt et al., 1986) . Apart from the effects of the ACTH(4-9) analog on cognition and functional recovery, modulatory effects of ACTHlike neuropeptides on convulsive behaviors have also been noticed (Klein and Livingstone, 1950; Torda and Wolff, 1952; Cottrell et al., 1982; Pentella et al., 1982; Willig and Lagenstein, 1982; Tartara et al., 1983; Goldman and Berman, 1984; Wamil et al., 1991) . Especially, Goldman et al. (1987) showed that chronic peptide treatment reduced the development of seizures in amygdala-kindled rats and that acute treatment counteracted the severity of seizures. These authors mentioned a possible effect of the ACTH(4-9) analog on the disruption of normal ionic distribution. The interaction between ACTH fragments and opioids has been studied and evidenced before (Gispen et al., 1975; Terenius et al., 1975; Fekete et al., 1983; Bertolini et al., 1986) but has never been further elucidated. Interestingly, the opioids also have both modulatory effects on neuroprotection, cognition and convulsive/anticonvulsive properties (Tortella, 1988; Bramham, 1992) . There is abundant evidence that FL-opioid receptor activation modulates NMDA receptor-mediated responses and thus a peptide interaction with opioids or NMDA receptor activity may have a common cause (Chen and Huang, 199 1; Rusin and Randic, 199 1; Huang, 1992) . The mechanism of action of opioids is complex and involves, among others, Ca2+ currents (Hescheler et al., 1987; Schroeder et al., 199 1) . Interestingly, the beneficial effect of an ACTH(4-10) analog (BIM 220 15) on recovery after spinal cord injury has been demonstrated to depend on Ca'+ levels (Calvet et al., 1992) .
The nature of the interaction of ACTH(4-9) and the behavioral consequences of NMDA receptor activation is far from conclusive and most probably indirect, but the involvement of both ACTH-like peptides and NMDA-like agents in the three common domains-acquisition of behavior, neuronal excitation, and neuronal survival-is intriguing and will enforce further studies on the underlying mechanisms.
